HEPLISAV-B Exposure in Pregnant Women and Their Offspring
common.study.values.description
“DV2-HBV-27: Observational Pregnancy Registry”
Purpose of the study is to evaluate pregnancy outcomes among women who received a dose of HEPLISAV-B within 28 days prior to conception or at any time during pregnancy
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-no
common.study.methods.is-healthy-no
Biological - HEPLISAV-B
This study is strictly observational. Administration of HEPLISAV-B, the schedule of office visits and all treatment regimens will be determined by the treating health care provider in the context of routine clinical care.
participant.views.study.view.additional
participant.views.study.view.scientific-title
HEPLISAV-B Pregnancy Registry: An Observational Study on the Safety of HEPLISAV-B Exposure in Pregnant Women and Their Offspring
common.study.values.clinical-trial-id
NCT03664648
participant.views.study.view.id
dBBrNd
